Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs ETHAMOLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.
Allergic rhinitis,Nasal congestion
FDA-approved: Treatment of esophageal varices that have recently bled to prevent rebleeding.,Off-label: Sclerotherapy of varicose veins, treatment of hemorrhoids, management of vascular malformations.
Adults: 100 mg orally twice daily.
5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 5-6 hours in adults with normal renal function; may be prolonged in renal impairment.
Not available; components may be metabolized via hepatic CYP enzymes.
Ethanolamine oleate is metabolized in the liver via oxidation and conjugation; exact enzymes are not well characterized.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Primarily renal excretion of unchanged drug and metabolites; >90% eliminated in urine within 24 hours, with less than 5% in feces.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Approximately 20-30% bound to plasma proteins, primarily albumin.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Volume of distribution is approximately 0.5-0.8 L/kg, indicating distribution into extracellular fluid.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Intravenous: 100%; intramuscular: approximately 90-95% due to first-pass metabolism.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment required for renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in Child-Pugh class A or B; no specific dose modification established.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Not recommended for use in children due to lack of safety and efficacy data.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
Use with caution; consider reduced dose due to increased risk of sclerotherapy complications. No specific dose adjustments established.
None
None explicitly required by FDA; however, severe adverse effects including anaphylaxis, renal failure, and esophageal ulceration have been reported.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Risk of anaphylaxis and hypersensitivity reactions; have emergency equipment available.,Risk of esophageal ulceration, stricture, or perforation when used for varices.,May cause hemolysis and hemoglobinuria; monitor renal function.,Use caution in patients with cardiopulmonary disease, as rapid injection may cause bradycardia or hypotension.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Known hypersensitivity to ethanolamine oleate or any component.,Active gastrointestinal bleeding (for elective sclerotherapy).,Severe hepatic impairment or portal hypertension with high risk of perforation.,Uncontrolled systemic infection.
No known food interactions with topical naftifine. No dietary restrictions required.
No specific food interactions. Avoid oral intake immediately after procedure until gag reflex returns.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and potential for fetal harm. No adequate, well-controlled studies in pregnant women.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
It is not known whether ethanolamine oleate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No specific dosing adjustments are recommended for pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect drug distribution, but no dose adjustment studies exist. Avoid use unless benefit clearly outweighs risk.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Ethamolin (ethanolamine oleate) is a sclerosing agent used for esophageal varices. Administer via intravariceal injection; maximum dose per session is 20 m L. Monitor for anaphylaxis, chest pain, and esophageal ulceration. Do not use in patients with known hypersensitivity to ethanolamine or oleic acid.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
This medication is injected into the veins in your esophagus to stop bleeding.,You may experience chest pain or difficulty swallowing after the procedure.,Avoid eating or drinking until the numbing medicine wears off to prevent choking.,Report any signs of allergic reaction, such as hives, difficulty breathing, or swelling.,Follow up with your doctor for repeat procedures as needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs ETHAMOLIN, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. ETHAMOLIN is a Sclerosing Agent that works by Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and ETHAMOLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of ETHAMOLIN is: 5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and ETHAMOLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. ETHAMOLIN is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.